Nerissa Kreher
Fortune : 448 701 $ au 31/07/2026
Fortune : 448 701 $ au 31/07/2026
Nerissa C.
Kreher is currently an Independent Director at Rezolute, Inc. since 2021, an Independent Director at Xeris Biopharma Holdings, Inc. starting in 2026, and Chief Medical Officer at Alltrna.
Former roles include Head-Medical Affairs & Clinical Development at Alexion Pharmaceuticals, Inc., Vice President & Global Head-Medical Affairs at Zafgen, Inc. from 2015 to 2016, Head-Medical Affairs & Clinical Development at EMD Serono, Inc., Head-Medical Affairs & Clinical Development at Shire Human Genetic Therapies, Inc., Chief Medical Officer at AVROBIO, Inc. in 2018, Chief Medical Officer at Tiburio Therapeutics, Inc. from 2019 to 2020, and Chief Medical Officer at Entrada Therapeutics, Inc. from 2020 to 2024.
Education includes a doctorate from East Carolina University, graduate studies at Indiana University, an MBA from Northeastern University, and undergraduate studies at The University of North Carolina at Chapel Hill and The University of North Carolina at Charlotte.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/07/2026 | 33 582 ( 0,02 % ) | 271 343 $ | 31/07/2026 | |
REZOLUTE, INC. 0,04 % | 19/11/2025 | 37 576 ( 0,04 % ) | 177 359 $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| REZOLUTE, INC. | Directeur/Membre du Conseil | 02/03/2021 |
| XERIS BIOPHARMA HOLDINGS, INC. | Directeur/Membre du Conseil | 01/07/2026 |
Alltrna
Alltrna Pharmaceuticals: MajorHealth Technology Develops tRNA-based medicines for genetic disorders | Directeur Technique/Scientifique/R&D | - |
| Sociétés | Poste | Fin |
|---|---|---|
| ENTRADA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2024 |
Tiburio Therapeutics, Inc.
Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnological research and developmental services | Directeur Technique/Scientifique/R&D | 01/10/2020 |
| TECTONIC THERAPEUTIC, INC. | Directeur Technique/Scientifique/R&D | 17/12/2018 |
| LARIMAR THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/07/2016 |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Develops human genetic therapies | Directeur Technique/Scientifique/R&D | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 15 |
|---|---|
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
Zafgen, Inc.
Zafgen, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company | Health Technology |
East Carolina University
East Carolina University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Indiana University
Indiana University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Northeastern University
Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of North Carolina at Chapel Hill
The University of North Carolina at Chapel Hill Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EMD Serono, Inc.
EMD Serono, Inc. Pharmaceuticals: MajorHealth Technology Develops recombinant prescription medicines | Health Technology |
Shire Human Genetic Therapies, Inc.
Shire Human Genetic Therapies, Inc. Medical SpecialtiesHealth Technology Develops human genetic therapies | Health Technology |
The University of North Carolina at Charlotte
The University of North Carolina at Charlotte Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rezolute, Inc.
Rezolute, Inc. Pharmaceuticals: MajorHealth Technology Develops transformative therapies for metabolic diseases related to chronic glucose imbalance | Health Technology |
AVROBIO, Inc.
AVROBIO, Inc. BiotechnologyHealth Technology Develops potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases in a single dose | Health Technology |
Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for rare neuromuscular diseases | Health Technology |
Tiburio Therapeutics, Inc.
Tiburio Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnological research and developmental services | Health Technology |
Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. BiotechnologyHealth Technology Develops and commercializes therapies | Health Technology |
Alltrna
Alltrna Pharmaceuticals: MajorHealth Technology Develops tRNA-based medicines for genetic disorders | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national